Trial Summary
What is the purpose of this trial?The purpose of this study is to determine the diagnostic utility of 89Zr-panitumumab to identify metastatic lesion(s) in subjects with head and neck squamous cell carcinoma (HNSCC).
Eligibility Criteria
Adults over 19 with a confirmed diagnosis of head and neck squamous cell carcinoma, including those with recurrent disease or new primary. They must have had a PET/CT scan within the last 30 days showing suspected metastatic lesions and meet certain blood, kidney, and liver function criteria. Excluded are pregnant/breastfeeding individuals, those with low magnesium/potassium levels, severe renal issues, known allergies to similar drugs, lung conditions like interstitial pneumonitis or pulmonary fibrosis, or recent significant cardiovascular events.Inclusion Criteria
My blood, kidney, and liver tests are within the required ranges.
I am 19 years old or older.
I have been diagnosed with head and neck cancer, regardless of its stage or if it has returned.
+2 more
Exclusion Criteria
I have severe kidney problems or cannot produce urine.
Pregnant or breastfeeding
Known hypersensitivity to deferoxamine or any of its components
+5 more
Participant Groups
The trial is testing the effectiveness of an intravenous drug called Zr-Panitumumab in detecting metastatic cancer lesions in patients with head and neck cancers when used alongside standard PET/CT scans.
2Treatment groups
Experimental Treatment
Active Control
Group I: 89Zr-panitumumab IVExperimental Treatment1 Intervention
Subjects will be given 89Zr-panitumumab IV
Group II: panitumumab 30 mgActive Control1 Intervention
Subjects will be given a 30mg of panitumumab
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Stanford Cancer InstituteSan Francisco, CA
Loading ...
Who Is Running the Clinical Trial?
Andrei IagaruLead Sponsor